Genetically modified cellular therapies for malignant gliomas

Despite extensive preclinical research on immunotherapeutic approaches, malignant glioma remains a devastating disease of the central nervous system for which standard of care treatment is still confined to resection and radiochemotherapy. For peripheral solid tumors, immune checkpoint inhibition ha...

Full description

Saved in:
Bibliographic Details
Main Authors: Kilian, Michael (Author) , Bunse, Theresa (Author) , Wick, Wolfgang (Author) , Platten, Michael (Author) , Bunse, Lukas (Author)
Format: Article (Journal)
Language:English
Published: 26 November 2021
In: International journal of molecular sciences
Year: 2021, Volume: 22, Issue: 23, Pages: 1-16
ISSN:1422-0067
DOI:10.3390/ijms222312810
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/ijms222312810
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1422-0067/22/23/12810
Get full text
Author Notes:Michael Kilian, Theresa Bunse, Wolfgang Wick, Michael Platten and Lukas Bunse

MARC

LEADER 00000caa a2200000 c 4500
001 1806818000
003 DE-627
005 20230427160759.0
007 cr uuu---uuuuu
008 220611s2021 xx |||||o 00| ||eng c
024 7 |a 10.3390/ijms222312810  |2 doi 
035 |a (DE-627)1806818000 
035 |a (DE-599)KXP1806818000 
035 |a (OCoLC)1341461328 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kilian, Michael  |d 1990-  |e VerfasserIn  |0 (DE-588)1220319422  |0 (DE-627)1736693255  |4 aut 
245 1 0 |a Genetically modified cellular therapies for malignant gliomas  |c Michael Kilian, Theresa Bunse, Wolfgang Wick, Michael Platten and Lukas Bunse 
264 1 |c 26 November 2021 
300 |a 16 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 11.06.2022 
520 |a Despite extensive preclinical research on immunotherapeutic approaches, malignant glioma remains a devastating disease of the central nervous system for which standard of care treatment is still confined to resection and radiochemotherapy. For peripheral solid tumors, immune checkpoint inhibition has shown substantial clinical benefit, while promising preclinical results have yet failed to translate into clinical efficacy for brain tumor patients. With the advent of high-throughput sequencing technologies, tumor antigens and corresponding T cell receptors (TCR) and antibodies have been identified, leading to the development of chimeric antigen receptors (CAR), which are comprised of an extracellular antibody part and an intracellular T cell receptor signaling part, to genetically engineer T cells for antigen recognition. Due to efficacy in other tumor entities, a plethora of CARs has been designed and tested for glioma, with promising signs of biological activity. In this review, we describe glioma antigens that have been targeted using CAR T cells preclinically and clinically, review their drawbacks and benefits, and illustrate how the emerging field of transgenic TCR therapy can be used as a potent alternative for cell therapy of glioma overcoming antigenic limitations. 
650 4 |a adoptive T cell transfer 
650 4 |a brain tumor 
650 4 |a CAR 
650 4 |a glioblastoma 
650 4 |a glioma 
650 4 |a TCR 
700 1 |a Bunse, Theresa  |d 1985-  |e VerfasserIn  |0 (DE-588)105282112X  |0 (DE-627)789079070  |0 (DE-576)408553731  |4 aut 
700 1 |a Wick, Wolfgang  |d 1970-  |e VerfasserIn  |0 (DE-588)120297736  |0 (DE-627)080586929  |0 (DE-576)186221320  |4 aut 
700 1 |a Platten, Michael  |d 1971-  |e VerfasserIn  |0 (DE-588)121627780  |0 (DE-627)081431848  |0 (DE-576)261969811  |4 aut 
700 1 |a Bunse, Lukas  |d 1988-  |e VerfasserIn  |0 (DE-588)1051941229  |0 (DE-627)787187399  |0 (DE-576)407600426  |4 aut 
773 0 8 |i Enthalten in  |t International journal of molecular sciences  |d Basel : Molecular Diversity Preservation International, 2000  |g 22(2021), 23, Artikel-ID 12810, Seite 1-16  |h Online-Ressource  |w (DE-627)316340715  |w (DE-600)2019364-6  |w (DE-576)281194653  |x 1422-0067  |7 nnas  |a Genetically modified cellular therapies for malignant gliomas 
773 1 8 |g volume:22  |g year:2021  |g number:23  |g elocationid:12810  |g pages:1-16  |g extent:16  |a Genetically modified cellular therapies for malignant gliomas 
856 4 0 |u https://doi.org/10.3390/ijms222312810  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.mdpi.com/1422-0067/22/23/12810  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220611 
993 |a Article 
994 |a 2022 
998 |g 1051941229  |a Bunse, Lukas  |m 1051941229:Bunse, Lukas  |d 60000  |d 62700  |e 60000PB1051941229  |e 62700PB1051941229  |k 0/60000/  |k 1/60000/62700/  |p 5  |y j 
998 |g 121627780  |a Platten, Michael  |m 121627780:Platten, Michael  |d 60000  |d 62700  |e 60000PP121627780  |e 62700PP121627780  |k 0/60000/  |k 1/60000/62700/  |p 4 
998 |g 120297736  |a Wick, Wolfgang  |m 120297736:Wick, Wolfgang  |d 910000  |d 911100  |e 910000PW120297736  |e 911100PW120297736  |k 0/910000/  |k 1/910000/911100/  |p 3 
998 |g 105282112X  |a Bunse, Theresa  |m 105282112X:Bunse, Theresa  |d 60000  |d 62700  |e 60000PB105282112X  |e 62700PB105282112X  |k 0/60000/  |k 1/60000/62700/  |p 2 
999 |a KXP-PPN1806818000  |e 4148129807 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 11.06.2022"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"title":[{"title_sort":"Genetically modified cellular therapies for malignant gliomas","title":"Genetically modified cellular therapies for malignant gliomas"}],"relHost":[{"disp":"Genetically modified cellular therapies for malignant gliomasInternational journal of molecular sciences","recId":"316340715","physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"International journal of molecular sciences","title":"International journal of molecular sciences"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 17.09.20"],"origin":[{"publisher":"Molecular Diversity Preservation International","dateIssuedKey":"2000","dateIssuedDisp":"2000-","publisherPlace":"Basel"}],"id":{"eki":["316340715"],"issn":["1422-0067","1661-6596"],"zdb":["2019364-6"]},"part":{"extent":"16","text":"22(2021), 23, Artikel-ID 12810, Seite 1-16","issue":"23","pages":"1-16","volume":"22","year":"2021"},"pubHistory":["1.2000 -"],"titleAlt":[{"title":"IJMS"}]}],"person":[{"display":"Kilian, Michael","role":"aut","given":"Michael","family":"Kilian"},{"family":"Bunse","role":"aut","given":"Theresa","display":"Bunse, Theresa"},{"family":"Wick","given":"Wolfgang","role":"aut","display":"Wick, Wolfgang"},{"family":"Platten","given":"Michael","role":"aut","display":"Platten, Michael"},{"given":"Lukas","role":"aut","family":"Bunse","display":"Bunse, Lukas"}],"origin":[{"dateIssuedDisp":"26 November 2021","dateIssuedKey":"2021"}],"physDesc":[{"extent":"16 S."}],"recId":"1806818000","id":{"doi":["10.3390/ijms222312810"],"eki":["1806818000"]},"name":{"displayForm":["Michael Kilian, Theresa Bunse, Wolfgang Wick, Michael Platten and Lukas Bunse"]}} 
SRT |a KILIANMICHGENETICALL2620